LakeShore Biopharma Co., Ltd (LSB)

NASDAQ: LSB · Real-Time Price · USD

0.8129

-0.0071 (-0.87%)

At close: Aug 26, 2025, 4:00 PM

0.7959

-0.0170 (-2.09%)

After-hours: Aug 26, 2025, 6:19 PM EDT

LakeShore Biopharma Employees

LakeShore Biopharma had 573 employees as of March 31, 2025. The number of employees decreased by 185 or -24.41% compared to the previous year.

Employees

573

Change (1Y)

-185

Growth (1Y)

-24.41%

Revenue / Employee

$147,899

Profits / Employee

-$24,046

Market Cap

33.50M

Employees Chart

Employees History

Date	Employees	Change	Growth
Mar 31, 2025	573	-185	-24.41%
Mar 31, 2024	758	-15	-1.94%
Mar 31, 2023	773	-92	-10.64%
Mar 31, 2022	865	-	-

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

LSB News

8 days ago - LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company - PRNewsWire
26 days ago - LakeShore Biopharma Announces Fiscal Year 2025 Financial Results - PRNewsWire
7 weeks ago - LakeShore Biopharma Announces US$15 Million Private Placement Financing - PRNewsWire
4 months ago - LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA™ Rabies Vaccine (Vero Cell) - PRNewsWire
8 months ago - LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance - PRNewsWire
9 months ago - LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China - GlobeNewsWire
10 months ago - LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
10 months ago - LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine - PRNewsWire